US6083903A
(en)
*
|
1994-10-28 |
2000-07-04 |
Leukosite, Inc. |
Boronic ester and acid compounds, synthesis and uses
|
US6838477B2
(en)
*
|
1995-04-12 |
2005-01-04 |
President And Fellows Of Harvard College |
Lactacystin analogs
|
FR2758329B1
(fr)
*
|
1997-01-16 |
1999-02-12 |
Synthelabo |
Derives d'imidazole-4-butane boronique, leur preparation et leur utilisation en therapeutique
|
AU741802B2
(en)
*
|
1997-02-15 |
2001-12-13 |
Millennium Pharmaceuticals, Inc. |
Treatment of infarcts through inhibition of NF-kappaB
|
US6221888B1
(en)
*
|
1997-05-29 |
2001-04-24 |
Merck & Co., Inc. |
Sulfonamides as cell adhesion inhibitors
|
WO1999015183A1
(en)
*
|
1997-09-25 |
1999-04-01 |
Proscript Inc. |
PROTEASOME INHIBITORS, UBIQUITIN PATHWAY INHIBITORS OR AGENTS THAT INTERFERE WITH THE ACTIVATION OF NF-λB VIA THE UBIQUITIN PROTEASOME PATHWAY TO TREAT INFLAMMATORY AND AUTOIMMUNE DISEASES
|
CN1163594C
(zh)
*
|
1997-09-29 |
2004-08-25 |
尖端医疗有限公司 |
体外造血细胞的刺激
|
US6831057B2
(en)
*
|
1997-10-28 |
2004-12-14 |
The University Of North Carolina At Chapel Hill |
Use of NF-κB inhibition in combination therapy for cancer
|
CA2219867A1
(en)
*
|
1997-10-31 |
1999-04-30 |
Jiangping Wu |
The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
|
DE19802450A1
(de)
*
|
1998-01-23 |
1999-07-29 |
Hoechst Marion Roussel De Gmbh |
Ustilipide, Verfahren zu deren Herstellung sowie deren Verwendung
|
US6075150A
(en)
*
|
1998-01-26 |
2000-06-13 |
Cv Therapeutics, Inc. |
α-ketoamide inhibitors of 20S proteasome
|
US6617171B2
(en)
*
|
1998-02-27 |
2003-09-09 |
The General Hospital Corporation |
Methods for diagnosing and treating autoimmune disease
|
FR2779653B1
(fr)
*
|
1998-06-11 |
2002-12-20 |
Inst Nat Sante Rech Med |
Utilisation de composes modulateurs du proteasome en therapie
|
US6902721B1
(en)
|
1998-07-10 |
2005-06-07 |
Osteoscreen, Inc. |
Inhibitors of proteasomal activity for stimulating bone growth
|
US6462019B1
(en)
|
1998-07-10 |
2002-10-08 |
Osteoscreen, Inc. |
Inhibitors of proteasomal activity and production for stimulating bone growth
|
US6838436B1
(en)
*
|
1998-07-10 |
2005-01-04 |
Osteoscreen Inc. |
Inhibitors of proteasomal activity for stimulating bone growth
|
US6979697B1
(en)
*
|
1998-08-21 |
2005-12-27 |
Point Therapeutics, Inc. |
Regulation of substrate activity
|
EP0982317A1
(en)
*
|
1998-08-26 |
2000-03-01 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Bivalent inhibitors of the proteasome
|
EP1123412B1
(en)
*
|
1998-10-20 |
2004-10-06 |
Millennium Pharmaceuticals, Inc. |
Method for monitoring proteasome inhibitor drug action
|
US6492333B1
(en)
*
|
1999-04-09 |
2002-12-10 |
Osteoscreen, Inc. |
Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors
|
US6890904B1
(en)
*
|
1999-05-25 |
2005-05-10 |
Point Therapeutics, Inc. |
Anti-tumor agents
|
US6649593B1
(en)
*
|
1999-10-13 |
2003-11-18 |
Tularik Inc. |
Modulators of SREBP processing
|
CA2419238A1
(en)
*
|
2000-08-16 |
2002-02-21 |
University Of Alberta |
Non-pressurized methods for the preparation of conjugated solid supports for boronic acids
|
US6919382B2
(en)
|
2000-08-31 |
2005-07-19 |
The Governors Of The University Of Alberta |
Preparation and uses of conjugated solid supports for boronic acids
|
ATE338564T1
(de)
*
|
2000-10-12 |
2006-09-15 |
Viromics Gmbh |
Proteasome inhibitoren zur behandlung von hepatitis-virus infektionen
|
FI2251344T4
(fi)
|
2001-01-25 |
2024-04-29 |
The United States Of America Represented By The Secretary |
Boronihappoyhdisteiden formulointi
|
AU2002308760B2
(en)
|
2001-05-21 |
2006-05-11 |
Alcon, Inc. |
Use of proteasome inhibitors to treat dry eye disorders
|
US7112588B2
(en)
*
|
2001-05-21 |
2006-09-26 |
Alcon, Inc. |
Use of proteasome inhibitors to treat dry eye disorders
|
PT1399468E
(pt)
*
|
2001-05-30 |
2006-05-31 |
Novartis Ag |
Derivados do acido 2-{[n-(2-amino-3-(heteroaril ou aril)propionil)-aminoacil]-amino}-alquilboronico
|
WO2003033506A1
(fr)
*
|
2001-10-12 |
2003-04-24 |
Kyorin Pharmaceutical Co., Ltd. |
Derive d'acide d'aminoborane et medicament inhibiteur de proteasomes le contenant
|
JPWO2003033507A1
(ja)
*
|
2001-10-12 |
2005-02-03 |
杏林製薬株式会社 |
ベンジルマロン酸誘導体およびそれを含有するプロテアソーム阻害薬
|
AU2003219652A1
(en)
|
2002-01-08 |
2003-07-30 |
Eisai Co. Ltd. |
Eponemycin and epoxomicin analogs and uses thereof
|
AU2003218232A1
(en)
*
|
2002-03-12 |
2003-09-29 |
Ariad Pharmaceuticals, Inc. |
Peptide analogues and uses thereof
|
AU2003212335B8
(en)
*
|
2002-03-13 |
2009-04-23 |
Janssen Pharmaceutica N.V. |
Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase
|
DK1485354T3
(da)
|
2002-03-13 |
2008-09-01 |
Janssen Pharmaceutica Nv |
Sulfonylamino-derivater som nye inhibitorer af histandeacetylase
|
NZ534831A
(en)
|
2002-03-13 |
2007-01-26 |
Janssen Pharmaceutica Nv |
Carbonylamino-derivatives having histone deacetylase (HDAC) inhibiting enzymatic activity
|
BR0307606A
(pt)
*
|
2002-03-13 |
2004-12-21 |
Janssen Pharmaceutica Nv |
Derivados de piperazinila, piperidinila e morfolinila como inibidores de histona desacetilase
|
US20050203029A1
(en)
*
|
2002-04-05 |
2005-09-15 |
Ulrich Schubert |
Agents for treating <I>flaviviridae</I>infections
|
US7514579B2
(en)
*
|
2002-06-13 |
2009-04-07 |
Johns Hopkins University |
Boronic chalcone derivatives and uses thereof
|
IL166157A0
(en)
*
|
2002-07-09 |
2006-01-15 |
Point Therapeutics Inc |
Methods and compositions relating to isoleucine boroproline compounds
|
EP1536777B1
(en)
*
|
2002-08-14 |
2007-02-14 |
Janssen Pharmaceutica N.V. |
Use of nf-kappa b inhibitors for the treatment of mastitis
|
US20050282757A1
(en)
*
|
2002-09-09 |
2005-12-22 |
Trigen Limited |
Peptide boronic acid compounds useful in anticoagulation
|
US20050119226A1
(en)
*
|
2003-09-09 |
2005-06-02 |
Trigen Limited |
Methods for synthesizing organoboronic compounds and products thereof
|
US7112572B2
(en)
*
|
2002-09-09 |
2006-09-26 |
Trigen Limited |
Multivalent metal salts of boronic acids
|
US20050176651A1
(en)
*
|
2002-09-09 |
2005-08-11 |
Trigen Limited |
Peptide boronic acids useful in making salts thereof
|
US20060084592A1
(en)
*
|
2002-09-09 |
2006-04-20 |
Trigen Limited |
Peptide boronic acid inhibitors
|
DE60305113T2
(de)
*
|
2002-09-09 |
2006-12-07 |
Trigen Ltd. |
Borsäuresalze und deren Verwendung in der Bereitstellung von Medikamente für die Thrombosebehandlung
|
PL374700A1
(en)
*
|
2002-09-20 |
2005-10-31 |
Alcon, Inc. |
Use of cytokine synthesis inhibitors for the treatment of dry eye disorders
|
CA2508348C
(en)
|
2002-12-06 |
2016-07-12 |
Millennium Pharmaceuticals, Inc. |
Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy
|
CN100341880C
(zh)
*
|
2003-02-13 |
2007-10-10 |
上海仁虎制药股份有限公司 |
新型硼酸或硼酸酯类化合物、制备方法及在药学上的应用
|
WO2005007211A2
(en)
*
|
2003-07-03 |
2005-01-27 |
Medtronic Vascular Inc. |
Medical devices with proteasome inhibitors for the treatment of restenosis
|
US7223745B2
(en)
*
|
2003-08-14 |
2007-05-29 |
Cephalon, Inc. |
Proteasome inhibitors and methods of using the same
|
US7576206B2
(en)
|
2003-08-14 |
2009-08-18 |
Cephalon, Inc. |
Proteasome inhibitors and methods of using the same
|
EP1682179A4
(en)
*
|
2003-11-05 |
2008-09-03 |
Palingen Inc |
INCREASED CYTOTOXICITY OF CDIM BINDING ANTIBODY AGAINST B LYMPHOCYTES
|
US20060052390A1
(en)
*
|
2003-12-24 |
2006-03-09 |
Scios, Inc. |
Treatment of multiple myeloma by p38 MAP kinase and proteasome inhibition
|
BRPI0507972A
(pt)
*
|
2004-02-23 |
2007-07-24 |
Tufts College |
composto ,composição farmacêutica , uso de um composto, método para inibição da atividade proteolìtica de uma enzima de clivagem pós prolina e composição farmacêutica embalada
|
GB0405272D0
(en)
*
|
2004-03-09 |
2004-04-21 |
Trigen Ltd |
Compounds
|
US7371875B2
(en)
*
|
2004-03-12 |
2008-05-13 |
Miikana Therapeutics, Inc. |
Cytotoxic agents and methods of use
|
AU2016202747B2
(en)
*
|
2004-03-30 |
2017-11-23 |
Millennium Pharmaceuticals, Inc. |
Synthesis of boronic ester and acid compounds
|
ES2457593T3
(es)
|
2004-03-30 |
2014-04-28 |
Millennium Pharmaceuticals, Inc. |
Síntesis de bortezomib
|
AU2005238445B2
(en)
|
2004-04-15 |
2012-05-03 |
Onyx Therapeutics, Inc. |
Compounds for enzyme inhibition
|
US8198270B2
(en)
|
2004-04-15 |
2012-06-12 |
Onyx Therapeutics, Inc. |
Compounds for proteasome enzyme inhibition
|
ES2510840T3
(es)
|
2004-05-10 |
2014-10-21 |
Onyx Therapeutics, Inc. |
Compuestos para la inhibición enzimática del proteosoma
|
EP2277595A3
(en)
|
2004-06-24 |
2011-09-28 |
Novartis Vaccines and Diagnostics, Inc. |
Compounds for immunopotentiation
|
EP1794120B1
(en)
|
2004-07-23 |
2012-04-11 |
Nuada, LLC |
Peptidase inhibitors
|
WO2006010750A1
(en)
|
2004-07-28 |
2006-02-02 |
Janssen Pharmaceutica N.V. |
Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
|
AU2005295183A1
(en)
|
2004-10-20 |
2006-04-27 |
CAOnyx Therapeutics, Inc. |
Labeled compounds for proteasome inhibition
|
AU2005304973A1
(en)
|
2004-11-05 |
2006-05-18 |
Palingen, Inc. |
Antibody induced cell membrane wounding
|
TW200618820A
(en)
*
|
2004-11-05 |
2006-06-16 |
Alza Corp |
Liposome formulations of boronic acid compounds
|
US8017395B2
(en)
|
2004-12-17 |
2011-09-13 |
Lifescan, Inc. |
Seeding cells on porous supports
|
US20070098685A1
(en)
*
|
2005-01-19 |
2007-05-03 |
Brand Stephen J |
Methods and kits to treat chronic inflammatory immune diseases by administering a proteasome inhibitor and an interleukin 2 receptor agonist
|
CA2594477C
(en)
|
2005-01-21 |
2016-07-12 |
Astex Therapeutics Limited |
Pharmaceutical compounds
|
US20090018146A1
(en)
*
|
2005-01-27 |
2009-01-15 |
Research Development Corporation |
Combination Therapy with Triterpenoid Compounds and Proteasome Inhibitors
|
US7468383B2
(en)
*
|
2005-02-11 |
2008-12-23 |
Cephalon, Inc. |
Proteasome inhibitors and methods of using the same
|
NZ560448A
(en)
*
|
2005-02-16 |
2009-08-28 |
Anacor Pharmaceuticals Inc |
Boron-containing small molecules
|
US7589066B2
(en)
*
|
2005-03-11 |
2009-09-15 |
The University Of North Carolina At Chapel Hill |
Potent and specific immunoproteasome inhibitors
|
WO2006119032A1
(en)
*
|
2005-04-29 |
2006-11-09 |
Kosan Biosciences Incorporated |
Method of treating multiple myeloma using 17-aag or 17-ag or a prodrug of either in combination with a proteasome inhibitor
|
EP1885710B1
(en)
|
2005-05-18 |
2015-08-19 |
Janssen Pharmaceutica N.V. |
Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase
|
AU2006202209B2
(en)
*
|
2005-05-27 |
2011-04-14 |
Lifescan, Inc. |
Amniotic fluid derived cells
|
SI1888123T1
(sl)
*
|
2005-06-08 |
2013-04-30 |
Janssen Biotech, Inc. |
Celična terapija za okularno degeneracijo
|
WO2007002972A2
(en)
*
|
2005-07-06 |
2007-01-11 |
Biodevelops Pharma Entwicklung Gmbh |
Use of a compound for enhancing the expression of membrane proteins on the cell surface
|
EP1752467A1
(en)
|
2005-08-10 |
2007-02-14 |
4Sc Ag |
Inhibitors of cancer cell, t-cell and keratinocyte proliferation
|
US7531517B2
(en)
|
2005-08-10 |
2009-05-12 |
4Sc Ag |
Inhibitors of cancer cell, T-cell and keratinocyte proliferation
|
US20070059382A1
(en)
*
|
2005-09-09 |
2007-03-15 |
Board Of Regents, Univ. And Comm. College System Of Nevada... |
Medical treatment of breast cancer with boric acid materials
|
PL2623113T3
(pl)
|
2005-11-09 |
2018-05-30 |
Onyx Therapeutics, Inc. |
Związek do hamowania enzymu
|
WO2007067752A2
(en)
*
|
2005-12-08 |
2007-06-14 |
Cytokinetics, Inc. |
Certain compositions and methods of treatment
|
CN106008571A
(zh)
*
|
2005-12-30 |
2016-10-12 |
安纳考尔医药公司 |
含硼的小分子
|
JP5137849B2
(ja)
*
|
2006-01-19 |
2013-02-06 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
ヒストンデアセチラーゼのインヒビターとしての置換インドリル−アルキル−アミノ−誘導体
|
AU2007206944B2
(en)
*
|
2006-01-19 |
2012-08-23 |
Janssen Pharmaceutica N.V. |
Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
|
SI1981874T1
(sl)
*
|
2006-01-19 |
2009-10-31 |
Janssen Pharmaceutica Nv |
Aminofenilni derivati kot novi inhibitorji histon deacetilaze
|
AU2007206942B2
(en)
|
2006-01-19 |
2012-08-23 |
Janssen Pharmaceutica N.V. |
Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
PE20070978A1
(es)
*
|
2006-02-14 |
2007-11-15 |
Novartis Ag |
COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
|
SI2719388T1
(sl)
|
2006-02-16 |
2019-06-28 |
Anacor Pharmaceuticals, Inc. |
Majhne molekule, polnjene z borom, kot učinkovine proti vnetjem
|
TW200808739A
(en)
*
|
2006-04-06 |
2008-02-16 |
Novartis Vaccines & Diagnostic |
Quinazolines for PDK1 inhibition
|
US8741643B2
(en)
*
|
2006-04-28 |
2014-06-03 |
Lifescan, Inc. |
Differentiation of pluripotent stem cells to definitive endoderm lineage
|
DE102006026464A1
(de)
|
2006-06-01 |
2007-12-06 |
Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma |
Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus
|
WO2007143600A2
(en)
*
|
2006-06-05 |
2007-12-13 |
Incyte Corporation |
Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases
|
EP2484688B1
(en)
|
2006-06-19 |
2016-06-08 |
Onyx Therapeutics, Inc. |
Peptide epoxyketones for proteasome inhibition
|
RU2456990C2
(ru)
*
|
2006-09-15 |
2012-07-27 |
Янссен Фармацевтика Нв |
Комбинации специфичных ингибиторов гистоновых деацетилаз класса i с ингибиторами протеасом
|
CA2659070C
(en)
*
|
2006-09-15 |
2014-10-21 |
Janssen Pharmaceutica Nv |
Histone deacetylase inhibitors with combined activity on class-i and class-iib histone deacetylases in combination with proteasome inhibitors
|
US8916552B2
(en)
|
2006-10-12 |
2014-12-23 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
EP2073807A1
(en)
|
2006-10-12 |
2009-07-01 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
CA2606634A1
(en)
*
|
2006-12-08 |
2008-06-08 |
Centenary Institute Of Cancer Medicine And Cell Biology |
Assay for response to proteasome inhibitors
|
JO3396B1
(ar)
|
2007-06-20 |
2019-10-20 |
Anacor Pharmaceuticals Inc |
جزيئات صغيرة تحتوي على البورون
|
US9080145B2
(en)
|
2007-07-01 |
2015-07-14 |
Lifescan Corporation |
Single pluripotent stem cell culture
|
CN101952415B
(zh)
|
2007-07-31 |
2017-06-27 |
生命扫描有限公司 |
人胚胎干细胞的分化
|
US8501713B2
(en)
|
2007-08-03 |
2013-08-06 |
Summit Corporation Plc |
Drug combinations for the treatment of duchenne muscular dystrophy
|
GB0715087D0
(en)
|
2007-08-03 |
2007-09-12 |
Summit Corp Plc |
Drug combinations for the treatment of duchenne muscular dystrophy
|
US7442830B1
(en)
|
2007-08-06 |
2008-10-28 |
Millenium Pharmaceuticals, Inc. |
Proteasome inhibitors
|
AU2016253697A1
(en)
*
|
2007-08-06 |
2016-11-24 |
Millennium Pharmaceuticals, Inc. |
Proteasome inhibitors
|
EA034601B1
(ru)
*
|
2007-08-06 |
2020-02-25 |
Милленниум Фармасьютикалз, Инк. |
Способ получения бороновых кислот
|
PT2178888E
(pt)
*
|
2007-08-06 |
2012-10-04 |
Millennium Pharm Inc |
Inibidores do proteassoma
|
JP2010539183A
(ja)
*
|
2007-09-12 |
2010-12-16 |
ドクター・レディーズ・ラボラトリーズ・リミテッド |
ボルテゾミブおよびその生成のためのプロセス
|
US20090076031A1
(en)
*
|
2007-09-17 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched bortezomib
|
US8367617B2
(en)
|
2007-10-04 |
2013-02-05 |
Onyx Therapeutics, Inc. |
Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
|
US7838673B2
(en)
*
|
2007-10-16 |
2010-11-23 |
Millennium Pharmaceuticals, Inc. |
Proteasome inhibitors
|
US20090110688A1
(en)
*
|
2007-10-24 |
2009-04-30 |
Georg Fertig |
Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor
|
CN107574142B
(zh)
*
|
2007-11-27 |
2021-07-06 |
生命扫描有限公司 |
人胚胎干细胞的分化
|
CN101220048B
(zh)
*
|
2007-12-14 |
2012-08-15 |
江苏先声药物研究有限公司 |
ZnCl2催化下的蒎烷二醇酯的制备方法
|
KR20100093129A
(ko)
|
2007-12-20 |
2010-08-24 |
노파르티스 아게 |
Pi 3 키나제 억제제로서 사용되는 티아졸 유도체
|
CN105886459A
(zh)
|
2008-02-21 |
2016-08-24 |
詹森生物科技公司 |
用于细胞粘附、培养和分离的方法、表面改性培养板和组合物
|
US8039450B2
(en)
|
2008-03-06 |
2011-10-18 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules as anti-inflammatory agents
|
EP2285384A4
(en)
*
|
2008-05-12 |
2012-04-25 |
Anacor Pharmaceuticals Inc |
BORN SMALL MOLECULES
|
EA201500431A1
(ru)
*
|
2008-06-17 |
2015-11-30 |
Милленниум Фармасьютикалз, Инк. |
Соединения боронатного эфира и его фармацевтические составы
|
CA2729121C
(en)
|
2008-06-30 |
2019-04-09 |
Centocor Ortho Biotech Inc. |
Differentiation of pluripotent stem cells
|
CN101638414B
(zh)
*
|
2008-07-30 |
2014-01-08 |
江苏先声药物研究有限公司 |
肽硼酸及其酯类化合物、制备方法及其用途
|
US20100028307A1
(en)
*
|
2008-07-31 |
2010-02-04 |
O'neil John J |
Pluripotent stem cell differentiation
|
WO2010027975A1
(en)
*
|
2008-09-04 |
2010-03-11 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules
|
WO2010028005A1
(en)
|
2008-09-04 |
2010-03-11 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules
|
AR075090A1
(es)
|
2008-09-29 |
2011-03-09 |
Millennium Pharm Inc |
Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
|
US9493489B2
(en)
*
|
2008-10-15 |
2016-11-15 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules as anti-protozoal agents
|
EP3090737A1
(en)
|
2008-10-21 |
2016-11-09 |
Onyx Therapeutics, Inc. |
Combination therapy with peptide epoxyketones
|
AU2009308967C1
(en)
|
2008-10-31 |
2017-04-20 |
Janssen Biotech, Inc. |
Differentiation of human embryonic stem cells to the pancreatic endocrine lineage
|
JP2012507289A
(ja)
|
2008-10-31 |
2012-03-29 |
ヤンセン バイオテツク,インコーポレーテツド |
ヒト胚性幹細胞の膵内分泌系への分化
|
CN102257132B
(zh)
*
|
2008-11-20 |
2014-09-03 |
森托科尔奥索生物科技公司 |
用于在平面基底上进行细胞附着和培养的方法和组合物
|
MX2011005288A
(es)
|
2008-11-20 |
2011-06-01 |
Centocor Ortho Biotech Inc |
Celulas madre pluripotentes en microportadores.
|
CN101747354B
(zh)
*
|
2008-12-04 |
2014-08-13 |
江苏先声药物研究有限公司 |
一类β氨基酸组成的二肽硼酸及其酯类化合物、制备方法及其用途
|
EA201190034A1
(ru)
*
|
2008-12-17 |
2012-02-28 |
Анакор Фармасьютикалс, Инк. |
Полиморфы (s)-3-аминометил-7-(3-гидроксипропокси)-3н-бензо[c][1,2]оксаборол-1-ола
|
CA2748921A1
(en)
|
2009-01-09 |
2010-08-12 |
Sun Pharma Advanced Research Company Limited |
Bortezumib containing pharmaceutical composition
|
EP2399129B1
(en)
|
2009-02-20 |
2015-11-25 |
Michael P. Lisanti |
A method of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm
|
CA2753285A1
(en)
|
2009-03-12 |
2010-09-16 |
Genentech, Inc. |
Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies
|
WO2010106135A1
(en)
|
2009-03-20 |
2010-09-23 |
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. |
Combined use for the treatment of ovarian carcinoma
|
AR075899A1
(es)
|
2009-03-20 |
2011-05-04 |
Onyx Therapeutics Inc |
Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
|
US9605317B2
(en)
*
|
2009-03-24 |
2017-03-28 |
Janssen Pharmaceutica Nv |
Biomarkers for assessing peripheral neuropathy response to cancer treatment
|
WO2010117668A1
(en)
*
|
2009-03-30 |
2010-10-14 |
Cerulean Pharma Inc. |
Polymer-agent conjugates, particles, compositions, and related methods of use
|
WO2010114770A1
(en)
*
|
2009-03-30 |
2010-10-07 |
Cerulean Pharma Inc. |
Polymer-agent conjugates, particles, compositions, and related methods of use
|
WO2010114768A1
(en)
*
|
2009-03-30 |
2010-10-07 |
Cerulean Pharma Inc. |
Polymer-epothilone conjugates, particles, compositions, and related methods of use
|
WO2010138141A1
(en)
*
|
2009-05-27 |
2010-12-02 |
Cephalon, Inc. |
Combination therapy for the treatment of multiple myeloma
|
EP2280016A1
(en)
|
2009-07-27 |
2011-02-02 |
LEK Pharmaceuticals d.d. |
New synthetic route for the preparation of alpha-amino boronic esters via substituted alk-1-ynes
|
CN101928329B
(zh)
|
2009-06-19 |
2013-07-17 |
北京大学 |
三肽硼酸(酯)类化合物、其制备方法和应用
|
WO2010146172A2
(en)
|
2009-06-19 |
2010-12-23 |
Lek Pharmaceuticals D.D. |
NEW SYNTHETIC ROUTE FOR THE PREPARATION OF α-AMINO BORONIC ACID DERIVATIVES VIA SUBSTITUTED ALK-1-YNES
|
EP2270019A1
(en)
|
2009-06-19 |
2011-01-05 |
LEK Pharmaceuticals d.d. |
New synthetic route for the preparation of alpha-amino boronic esters
|
US8293753B2
(en)
|
2009-07-02 |
2012-10-23 |
Novartis Ag |
Substituted 2-carboxamide cycloamino ureas
|
DE102009027754A1
(de)
|
2009-07-15 |
2011-05-05 |
Schubert, Ulrich, Dr. |
Verfahren zur Hemmung der Reifung von dendritischen Zellen
|
WO2011011349A2
(en)
|
2009-07-20 |
2011-01-27 |
Centocor Ortho Biotech Inc. |
Differentiation of human embryonic stem cells
|
ES2693088T3
(es)
*
|
2009-07-20 |
2018-12-07 |
Janssen Biotech, Inc. |
Diferenciación de células madre embriónicas humanas
|
JP6219568B2
(ja)
|
2009-07-20 |
2017-10-25 |
ヤンセン バイオテツク,インコーポレーテツド |
ヒト胚性幹細胞の分化
|
EP2458995A1
(en)
*
|
2009-07-28 |
2012-06-06 |
Anacor Pharmaceuticals, Inc. |
Trisubstituted boron-containing molecules
|
WO2011019618A1
(en)
*
|
2009-08-14 |
2011-02-17 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules as antiprotozoal agents
|
US20120149663A1
(en)
|
2009-08-18 |
2012-06-14 |
Georgetown University |
Boronic acid compositions and methods related to cancer
|
MX2012002031A
(es)
*
|
2009-08-19 |
2012-07-04 |
Anacor Pharmaceuticals Inc |
Moleculas pequeñas que contienen boro como agentes antiprotozoarios.
|
CA2770252C
(en)
|
2009-09-08 |
2018-06-12 |
F. Hoffmann-La Roche Ag |
4-substituted pyridin-3-yl-carboxamide compounds and uses thereof for treating cancer
|
US20110124597A1
(en)
*
|
2009-09-25 |
2011-05-26 |
Anacor Pharmaceuticals, Inc. |
Boron containing small molecules
|
EP2305285A1
(en)
|
2009-09-29 |
2011-04-06 |
Julius-Maximilians-Universität Würzburg |
Means and methods for treating ischemic conditions
|
JP2013506626A
(ja)
|
2009-10-01 |
2013-02-28 |
ヤンセン ファーマシューティカ エヌ.ベー. |
癌治療用のプロテアソーム阻害剤
|
US9346834B2
(en)
|
2009-10-20 |
2016-05-24 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules as antiprotozoal agents
|
WO2011060196A1
(en)
*
|
2009-11-11 |
2011-05-19 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules
|
US8853147B2
(en)
|
2009-11-13 |
2014-10-07 |
Onyx Therapeutics, Inc. |
Use of peptide epoxyketones for metastasis suppression
|
JP5783659B2
(ja)
|
2009-12-22 |
2015-09-24 |
セファロン、インク. |
プロテアソーム阻害剤およびその調製、精製および使用のための方法
|
RU2586506C2
(ru)
|
2009-12-23 |
2016-06-10 |
Янссен Байотек, Инк. |
Дифференцировка человеческих эмбриональных стволовых клеток
|
BR112012017761A2
(pt)
|
2009-12-23 |
2015-09-15 |
Centocor Ortho Biotech Inc |
diferenciação das células-tronco embrionárias humanas
|
US20110178287A1
(en)
|
2010-01-19 |
2011-07-21 |
Cerulean Pharma Inc. |
Cyclodextrin-based polymers for therapeutic delivery
|
WO2011094450A1
(en)
|
2010-01-27 |
2011-08-04 |
Anacor Pharmaceuticals, Inc |
Boron-containing small molecules
|
US9969981B2
(en)
|
2010-03-01 |
2018-05-15 |
Janssen Biotech, Inc. |
Methods for purifying cells derived from pluripotent stem cells
|
JP6042724B2
(ja)
|
2010-03-01 |
2016-12-14 |
オニキス セラピューティクス, インク.Onyx Therapeutics, Inc. |
イムノプロテアソーム阻害のための化合物
|
NZ602392A
(en)
*
|
2010-03-18 |
2014-03-28 |
Innopharma Inc |
Stable bortezomib formulations
|
US8263578B2
(en)
|
2010-03-18 |
2012-09-11 |
Innopharma, Inc. |
Stable bortezomib formulations
|
WO2011116348A1
(en)
|
2010-03-19 |
2011-09-22 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules as anti-protozoal agent
|
EP2550362B1
(en)
|
2010-03-25 |
2017-01-04 |
Oregon Health&Science University |
Cmv glycoproteins and recombinant vectors
|
AU2013204868B2
(en)
*
|
2010-03-31 |
2016-10-13 |
Millennium Pharmaceuticals, Inc. |
Derivatives of 1-amino-2-cyclopropylethylboronic acid
|
NZ602622A
(en)
|
2010-03-31 |
2015-01-30 |
Millennium Pharm Inc |
Derivatives of 1-amino-2-cyclopropylethylboronic acid
|
EP2555621A4
(en)
|
2010-04-07 |
2014-07-02 |
Onyx Therapeutics Inc |
CRYSTALLINE EPOXYCETONE PEPTIDE IMMUNOPROTEASOME INHIBITOR
|
CN101812026B
(zh)
*
|
2010-04-12 |
2013-08-28 |
亚邦医药股份有限公司 |
一种硼替佐米的合成方法
|
JP5801378B2
(ja)
|
2010-04-19 |
2015-10-28 |
ニーキ ファーマ インコーポレイテッド |
プロテアソーム阻害剤およびガリウム錯体を用いた併用療法
|
US8809282B2
(en)
|
2010-05-06 |
2014-08-19 |
Duke University |
Method of reducing titers of antibodies specific for a therapeutic agent
|
MX351515B
(es)
|
2010-05-12 |
2017-10-17 |
Janssen Biotech Inc |
Diferenciacion de celulas madre embrionarias humanas.
|
MX2012013100A
(es)
|
2010-05-18 |
2013-01-22 |
Cerulean Pharma Inc |
Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades.
|
AR082418A1
(es)
|
2010-08-02 |
2012-12-05 |
Novartis Ag |
Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
|
ES2658146T3
(es)
|
2010-08-31 |
2018-03-08 |
Janssen Biotech, Inc. |
Diferenciación de células madre embrionarias humanas
|
RU2599420C2
(ru)
|
2010-08-31 |
2016-10-10 |
Янссен Байотек, Инк. |
Дифференцирование плюрипотентных стволовых клеток
|
BR112013004616A2
(pt)
|
2010-08-31 |
2016-07-05 |
Janssen Biotech Inc |
diferenciação das células tronco embrionárias humanas
|
US9126997B1
(en)
|
2010-09-07 |
2015-09-08 |
Northwestern University |
Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma
|
ES2898695T3
(es)
|
2010-09-07 |
2022-03-08 |
Anacor Pharmaceuticals Inc |
Derivados de benzoxaborol para el tratamiento de infecciones bacterianas
|
US8962572B2
(en)
|
2010-10-05 |
2015-02-24 |
Fresenius Kabi Usa, Llc |
Bortezomib formulations
|
WO2012048745A1
(en)
|
2010-10-14 |
2012-04-19 |
Synthon Bv |
Process for making bortezomib and intermediates for the process
|
CN103476777B
(zh)
|
2011-01-31 |
2015-05-27 |
诺瓦提斯公司 |
新杂环衍生物
|
TW201309303A
(zh)
*
|
2011-03-03 |
2013-03-01 |
Cephalon Inc |
用於治療狼瘡的蛋白酶體抑制劑
|
US9272014B2
(en)
|
2011-03-29 |
2016-03-01 |
Texas Tech University System |
Galectin-3C combination therapy for human cancer
|
EP2692777B1
(en)
|
2011-03-31 |
2018-10-31 |
NanoCarrier Co., Ltd. |
Pharmaceutical composition containing block copolymer comprising boronic acid compound
|
PT2691530T
(pt)
|
2011-06-10 |
2018-05-10 |
Univ Oregon Health & Science |
Glicoproteínas e vectores recombinantes cmv
|
US20140121182A1
(en)
*
|
2011-06-22 |
2014-05-01 |
Cephalon, Inc. |
Proteasome inhibitors and processes for their preparation, purification and use
|
US8481655B2
(en)
|
2011-07-27 |
2013-07-09 |
Wacker Chemical Corporation |
Copper complexes of amino-functional organosilicon compounds and their use
|
WO2013021032A1
(en)
|
2011-08-11 |
2013-02-14 |
Janssen Pharmaceutica Nv |
Histone deacetylase inhibitors in combination with proteasome inhibitors and dexamethasone
|
SI2742356T1
(sl)
|
2011-08-11 |
2016-06-30 |
Janssen Pharmaceutica N.V. |
Prediktorji pri zdravljenju raka
|
ME02588B
(me)
|
2011-08-19 |
2017-06-20 |
Glaxo Group Ltd |
Jedinjenja benzofurana za lečenje virusnih infekcija hepatitisa c
|
AU2012301810B2
(en)
*
|
2011-08-30 |
2017-06-01 |
Trustees Of Tufts College |
FAP-activated proteasome inhibitors for treating solid tumors
|
US20130189754A1
(en)
|
2011-09-12 |
2013-07-25 |
International Aids Vaccine Initiative |
Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
|
US9402894B2
(en)
|
2011-10-27 |
2016-08-02 |
International Aids Vaccine Initiative |
Viral particles derived from an enveloped virus
|
CN104302180B
(zh)
|
2011-10-28 |
2017-05-17 |
米伦纽姆医药公司 |
对nedd8活化酶(nae)抑制剂的反应的生物标记
|
PL2771342T3
(pl)
|
2011-10-28 |
2016-11-30 |
|
Nowe pochodne puryny i ich zastosowanie w leczeniu chorób
|
EP2776043B1
(en)
|
2011-11-11 |
2018-02-21 |
Millennium Pharmaceuticals, Inc. |
Biomarkers of response to proteasome inhibitors
|
US20150184246A1
(en)
|
2011-11-11 |
2015-07-02 |
Millennium Pharmaceuticals, Inc. |
Biomarkers of response to proteasome inhibitors
|
KR101912978B1
(ko)
|
2011-11-17 |
2018-10-29 |
도꾜 다이가꾸 |
페닐보론산기가 도입된 블록 공중합체 및 그의 용도
|
KR102090751B1
(ko)
|
2011-12-22 |
2020-03-19 |
얀센 바이오테크 인코포레이티드 |
인간 배아 줄기 세포의 단일 인슐린 호르몬 양성 세포로의 분화
|
US9732101B2
(en)
|
2012-01-18 |
2017-08-15 |
Wisconsin Alumni Research Foundation |
Bioreversible boronates for delivery of molecules into cells
|
WO2013110005A1
(en)
|
2012-01-18 |
2013-07-25 |
Wisconsin Alumni Research Foundation |
Boronate-mediated delivery of molecules into cells
|
EP2810066B1
(en)
|
2012-01-24 |
2019-07-31 |
Millennium Pharmaceuticals, Inc. |
Methods of treatment of cancer
|
GB2523211B
(en)
|
2012-01-27 |
2020-03-18 |
Univ Jefferson |
MCT protein inhibitor-related prognostic and therapeutic methods
|
CA2863714C
(en)
|
2012-02-08 |
2022-07-05 |
Igm Biosciences, Inc. |
Cdim binding proteins and uses thereof
|
WO2013128419A2
(en)
|
2012-03-02 |
2013-09-06 |
Dr. Reddy's Laboratories Limited |
Pharmaceutical compositions comprising boronic acid compounds
|
WO2013134378A1
(en)
|
2012-03-07 |
2013-09-12 |
Janssen Biotech, Inc. |
Defined media for expansion and maintenance of pluripotent stem cells
|
CA2784240C
(en)
|
2012-03-27 |
2014-07-08 |
Innopharma, Inc. |
Stable bortezomib formulations
|
RU2630975C2
(ru)
|
2012-05-16 |
2017-09-15 |
Новартис Аг |
Режим дозирования pi-3 киназы
|
DK3450542T3
(da)
|
2012-06-08 |
2021-11-01 |
Janssen Biotech Inc |
Differentiering af humane embryonale stamceller til endokrine pancreatiske celler
|
ES2631608T3
(es)
|
2012-06-27 |
2017-09-01 |
International Aids Vaccine Initiative |
Variante de la glicoproteína Env del VIH-1
|
TW201414751A
(zh)
|
2012-07-09 |
2014-04-16 |
歐尼克斯治療公司 |
肽環氧酮蛋白酶抑制劑之前驅藥物
|
JP2013006855A
(ja)
*
|
2012-09-03 |
2013-01-10 |
Millennium Pharmaceuticals Inc |
プロテアソーム阻害剤
|
US9505787B2
(en)
*
|
2012-09-11 |
2016-11-29 |
Cipla Limited |
Process for preparing of bortezomib
|
WO2014055543A2
(en)
|
2012-10-01 |
2014-04-10 |
Millennium Pharmaceuticals, Inc. |
Biomarkers and methods to predict response to inhibitors and uses thereof
|
WO2014072985A1
(en)
|
2012-11-06 |
2014-05-15 |
Natco Pharma Limited |
Novel boronic acid derivatives as anti cancer agents
|
US9217001B2
(en)
|
2012-11-16 |
2015-12-22 |
Shilpa Medicare Limited |
Crystalline bortezomib process
|
WO2014097306A1
(en)
|
2012-12-21 |
2014-06-26 |
Natco Pharma Limited |
Stable and pure polymorphic form of bortezomib
|
SG11201505112SA
(en)
|
2012-12-31 |
2015-07-30 |
Janssen Biotech Inc |
Differentiation of human embryonic stem cells into pancreatic endocrine cells using hb9 regulators
|
US10370644B2
(en)
|
2012-12-31 |
2019-08-06 |
Janssen Biotech, Inc. |
Method for making human pluripotent suspension cultures and cells derived therefrom
|
CN105705634A
(zh)
|
2012-12-31 |
2016-06-22 |
詹森生物科技公司 |
用于分化成胰腺内分泌细胞的人多能细胞的悬浮和群集
|
RU2018116647A
(ru)
|
2012-12-31 |
2018-10-24 |
Янссен Байотек, Инк. |
Культивация эмбриональных стволовых клеток человека в воздушно-жидкостной зоне взаимодействия с целью их дифференцировки в панкреатические эндокринные клетки
|
PT2968316T
(pt)
|
2013-03-13 |
2019-10-29 |
Forma Therapeutics Inc |
Derivados de 2-hidroxi-1-{4-[(4-fenilfenil)carbonil]piperazin-1-il}etano-1-ona e compostos relacionados como inibidores da sintase de ácidos gordos (fasn) para o tratamento do cancro
|
CA2909519A1
(en)
|
2013-04-16 |
2014-10-23 |
Cipla Limited |
Process for the preparation of bortezomib mannitol ester
|
US10022372B2
(en)
|
2013-04-19 |
2018-07-17 |
Thomas Jefferson University |
Caveolin-1 related methods for treating glioblastoma with temozolomide
|
US9603775B2
(en)
|
2013-04-24 |
2017-03-28 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US10478445B2
(en)
|
2013-07-03 |
2019-11-19 |
Georgetown University |
Boronic acid derivatives of resveratrol for activating deacetylase enzymes
|
US20150065381A1
(en)
|
2013-09-05 |
2015-03-05 |
International Aids Vaccine Initiative |
Methods of identifying novel hiv-1 immunogens
|
CA2925935A1
(en)
|
2013-10-03 |
2015-04-09 |
Millennium Pharmaceuticals, Inc. |
Method for the prophylaxis or treatment of systemic lupus erythematosus and/or lupus nephritis
|
EP2873423B1
(en)
|
2013-10-07 |
2017-05-31 |
International Aids Vaccine Initiative |
Soluble hiv-1 envelope glycoprotein trimers
|
CN104586776B
(zh)
*
|
2013-10-30 |
2017-05-17 |
扬子江药业集团上海海尼药业有限公司 |
以硼替佐米为活性成分的制剂及其制备方法
|
JP6468562B2
(ja)
*
|
2013-11-21 |
2019-02-13 |
国立大学法人北海道大学 |
プロテアソーム阻害性化合物
|
EP3633381A3
(en)
|
2013-12-05 |
2020-07-29 |
The Broad Institute, Inc. |
Compositions and methods for identifying and treating cachexia or pre-cachexia
|
KR20160095035A
(ko)
|
2013-12-06 |
2016-08-10 |
노파르티스 아게 |
알파-이소형 선택성 포스파티딜이노시톨 3-키나제 억제제를 위한 투여 요법
|
EP3102585B1
(en)
|
2014-02-03 |
2021-05-19 |
Ohio State Innovation Foundation |
Boronic acid esters and pharmaceutical formulations thereof
|
EP2910557A1
(en)
*
|
2014-02-20 |
2015-08-26 |
Ikerchem, S.L. |
Enantiopure tetrasubstituted pyrrolidines as scaffolds for proteasome inhibitors and medicinal applications thereof
|
US10993960B1
(en)
|
2014-05-08 |
2021-05-04 |
Kawasaki Institute Of Industrial Promotion |
Pharmaceutical composition
|
RU2694311C2
(ru)
|
2014-05-16 |
2019-07-11 |
Янссен Байотек, Инк. |
Применение малых молекул для увеличения экспрессии mafa в панкреатических эндокринных клетках
|
US20150335668A1
(en)
|
2014-05-20 |
2015-11-26 |
Millennium Pharmaceuticals, Inc. |
Method for cancer therapy
|
EP3808349B1
(en)
|
2014-08-07 |
2022-10-05 |
Mayo Foundation for Medical Education and Research |
Compounds and methods for treating cancer
|
AU2015327412B2
(en)
*
|
2014-10-01 |
2020-01-16 |
Merck Patent Gmbh |
Boronic acid derivatives
|
WO2016110870A1
(en)
|
2015-01-07 |
2016-07-14 |
Emcure Pharmaceuticals Limited |
Pharmaceutical composition of bortezomid
|
MA41505A
(fr)
|
2015-02-11 |
2017-12-19 |
Millennium Pharm Inc |
Nouvelle forme cristalline d'un inhibiteur de protéasome
|
WO2016146516A1
(en)
|
2015-03-17 |
2016-09-22 |
Leon-Nanodrugs Gmbh |
Nanoparticles comprising a stabilized boronic acid compound
|
EP3069730A3
(en)
|
2015-03-20 |
2017-03-15 |
International Aids Vaccine Initiative |
Soluble hiv-1 envelope glycoprotein trimers
|
EP3072901A1
(en)
|
2015-03-23 |
2016-09-28 |
International Aids Vaccine Initiative |
Soluble hiv-1 envelope glycoprotein trimers
|
WO2016184793A1
(en)
|
2015-05-15 |
2016-11-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for treating a patient with vegfr inhibitor-resistant metastatic renal cell carcinoma
|
US10144761B2
(en)
|
2015-06-19 |
2018-12-04 |
Hanlin Scientific Inc. |
Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis
|
EP3120836A1
(de)
|
2015-07-22 |
2017-01-25 |
Stada Arzneimittel Ag |
Gebrauchsfertige bortezomib-lösung
|
EP3120837A1
(de)
|
2015-07-22 |
2017-01-25 |
Stada Arzneimittel Ag |
Verfahren zur herstellung einer bortezomibester-lösung
|
CN106478700B
(zh)
*
|
2015-08-26 |
2020-12-29 |
杭州雷索药业有限公司 |
硼基取代的苯胺类蛋白激酶抑制剂
|
CN106588965A
(zh)
*
|
2015-10-15 |
2017-04-26 |
北京大学 |
脲拟肽硼酸化合物及其药物组合物、制备方法和用途
|
MX2018005298A
(es)
|
2015-11-02 |
2018-06-22 |
Novartis Ag |
Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa.
|
US11111296B2
(en)
|
2015-12-14 |
2021-09-07 |
The Broad Institute, Inc. |
Compositions and methods for treating cardiac dysfunction
|
CN107151255A
(zh)
*
|
2016-03-06 |
2017-09-12 |
复旦大学 |
硼酸类化合物及其制备方法和用途
|
CN107151254A
(zh)
*
|
2016-03-06 |
2017-09-12 |
复旦大学 |
一种作为20s蛋白酶体抑制剂的硼酸类化合物及其制备方法
|
MA45479A
(fr)
|
2016-04-14 |
2019-02-20 |
Janssen Biotech Inc |
Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen
|
US11447506B2
(en)
|
2016-05-09 |
2022-09-20 |
Anacor Pharmaceuticals, Inc. |
Crystal forms of crisaborole in free form and preparation method and use thereof
|
CN106008572B
(zh)
*
|
2016-05-23 |
2018-08-17 |
成都千禧莱医药科技有限公司 |
一类二肽硼酸化合物及制备方法和用途
|
US10526315B2
(en)
|
2016-06-21 |
2020-01-07 |
Orion Ophthalmology LLC |
Carbocyclic prolinamide derivatives
|
EA201990069A1
(ru)
|
2016-06-21 |
2019-06-28 |
ОРИОН ОФТАЛМОЛОДЖИ ЭлЭлСи |
Производные гетероциклического пролинамида
|
JP6681284B2
(ja)
*
|
2016-06-23 |
2020-04-15 |
信越化学工業株式会社 |
糖アルコール化合物の金属低減方法
|
JP6223508B2
(ja)
*
|
2016-06-27 |
2017-11-01 |
ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. |
プロテアソーム阻害剤
|
WO2018038687A1
(en)
|
2016-08-22 |
2018-03-01 |
Mustafa Nevzat Ilaç Sanayii A.Ş. |
Pharmaceutical formulations comprising a bortezomib-cyclodextrin complex
|
WO2018060833A1
(en)
|
2016-09-27 |
2018-04-05 |
Novartis Ag |
Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
|
CA3040820A1
(en)
|
2016-10-20 |
2018-04-26 |
Pfizer Inc. |
Therapeutic particles with peptide boronic acid or boronate ester compounds and methods of making and using same
|
US11584733B2
(en)
|
2017-01-09 |
2023-02-21 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
WO2018129533A1
(en)
|
2017-01-09 |
2018-07-12 |
Shuttle Pharmaceuticals, Llc |
Selective histone deacetylase inhibitors for the treatment of human disease
|
AU2018221670B2
(en)
|
2017-02-17 |
2021-02-04 |
Fresenius Kabi Oncology Ltd. |
An improved process for the preparation of boronic acid esters
|
US11596629B2
(en)
|
2017-02-28 |
2023-03-07 |
Mayo Foundation For Medical Education And Research |
Compounds and methods for treating cancer
|
CN117338932A
(zh)
|
2017-08-23 |
2024-01-05 |
科智生命科学公司 |
自身免疫性病症的治疗中的免疫蛋白酶体抑制剂和免疫抑制剂
|
EP3694878A1
(en)
|
2017-09-14 |
2020-08-19 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination treatment for cancer
|
JP2018024694A
(ja)
*
|
2017-10-03 |
2018-02-15 |
ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. |
プロテアソーム阻害剤
|
EP3710458A1
(en)
|
2017-11-16 |
2020-09-23 |
Principia Biopharma Inc. |
Immunoproteasome inhibitors
|
US20230133165A1
(en)
*
|
2017-11-16 |
2023-05-04 |
Principia Biopharma Inc. |
Immunoproteasome inhibitors
|
US10537585B2
(en)
|
2017-12-18 |
2020-01-21 |
Dexcel Pharma Technologies Ltd. |
Compositions comprising dexamethasone
|
EP3737376B1
(en)
|
2018-01-09 |
2024-04-17 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human diseases
|
CN111867573A
(zh)
|
2018-01-29 |
2020-10-30 |
科诺斯治疗学公司 |
硼替佐米的瘤内递送
|
WO2019178438A1
(en)
|
2018-03-15 |
2019-09-19 |
Abbvie Inc. |
Abbv-621 in combination with anti-cancer agents for the treatment of cancer
|
US11243207B2
(en)
|
2018-03-29 |
2022-02-08 |
Mayo Foundation For Medical Education And Research |
Assessing and treating cancer
|
CN113382633A
(zh)
|
2018-10-29 |
2021-09-10 |
福马治疗股份有限公司 |
(4-(2-氟-4-(1-甲基-1H-苯并[d]咪唑-5-基)苯甲酰基)哌嗪-1-基)(1-羟基环丙基)甲酮的固体形式
|
CN109824756B
(zh)
*
|
2019-03-19 |
2022-03-22 |
山东大学 |
含有4-(苯磺酰基)哌嗪-2-酮的苯丙氨酸衍生物及其制备方法与应用
|
CN114437119A
(zh)
*
|
2020-10-30 |
2022-05-06 |
苏州开拓药业股份有限公司 |
一种c-Myc蛋白抑制剂及其制备方法和用途
|
JP2023553011A
(ja)
*
|
2020-12-02 |
2023-12-20 |
ホフマン・テクノロジーズ・エルエルシー |
非ヒト哺乳動物においてがんを調節するための組成物および方法
|
TW202237143A
(zh)
*
|
2020-12-10 |
2022-10-01 |
南韓商Lg化學股份有限公司 |
酸(Boronic Acid)化合物
|
US11964993B2
(en)
|
2021-07-03 |
2024-04-23 |
Shilpa Pharma Lifesciences Limited |
Crystalline bortezomib process
|
US20230062279A1
(en)
|
2021-08-12 |
2023-03-02 |
Extrovis Ag |
Pharmaceutical compositions of bortezomib
|
CN113957441B
(zh)
*
|
2021-10-29 |
2024-01-02 |
光华科学技术研究院(广东)有限公司 |
蚀刻液及其制备方法和应用
|
WO2023220655A1
(en)
|
2022-05-11 |
2023-11-16 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
WO2023220641A2
(en)
|
2022-05-11 |
2023-11-16 |
Juno Therapeutics, Inc. |
Methods and uses related to t cell therapy and production of same
|
WO2024097905A1
(en)
|
2022-11-02 |
2024-05-10 |
Celgene Corporation |
Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
|